REFRACTORY MULTIPLE MYELOMA

This study is testing whether a drug called elranatamab can help prevent multiple myeloma from returning or worsening after patients receive a specialized CAR-T cell therapy. The research involves 32 adults with relapsed or hard-to-treat multiple myeloma who have already undergon…

This early-phase study is testing the safety of a new type of CAR T-cell therapy called BCMA-CD19 cCAR in patients with advanced multiple myeloma or plasmacytoid lymphoma who have no other treatment options left. The therapy uses a patient's own modified immune cells to attack ca…

This study is testing whether doctors can safely lower the dose of a cancer drug called linvoseltamab for people with multiple myeloma that has come back or stopped responding to other treatments. The goal is to see if less frequent, lower doses can still control the cancer while…

This is an early-stage study to test the safety of a new type of personalized cell therapy called TriPRIL CAR T cells in adults with multiple myeloma that has come back or stopped responding to standard treatments. Researchers will first find the safest dose and then treat more p…

This early-stage study is testing the safety and best dose of a new three-drug combination for people with multiple myeloma that has come back or stopped responding to other treatments. The treatment combines two drugs that help the immune system attack cancer cells with a steroi…

This study is testing a combination of four drugs—isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to prior treatments. The main goal is to see how well this combination shrinks the cancer.…

This study is testing whether a combination of three drugs (elotuzumab, iberdomide, and dexamethasone) can help keep multiple myeloma in remission for longer after patients receive a specialized cell therapy called ide-cel (CAR-T). The goal is to prevent or delay the cancer from …

This study is testing whether adding a new drug called iberdomide to an existing two-drug therapy is safe and more effective for people with multiple myeloma that has come back or stopped responding to other treatments. The trial will first find the safest dose of the three-drug …

This study is testing whether adding two drugs, dasatinib and quercetin, to a standard CAR-T cell therapy regimen works better for patients with multiple myeloma that has returned or stopped responding to other treatments. The goal is to see if this combination helps the CAR-T ce…

This study is testing whether a different dosing schedule for the drug elranatamab can make treatment safer and allow patients with advanced multiple myeloma to receive it as outpatients. The trial involves 40 patients whose cancer has returned or stopped responding to at least t…

This early-stage study is testing the safety and best dose of a new two-drug combination for multiple myeloma that has come back or stopped responding to other treatments. The trial combines an oral pill (iberdomide) that targets cancer cell proteins with an injected immunotherap…

This study is testing a combination of four medications to control multiple myeloma that has returned or stopped responding to prior treatments. It will involve about 43 adults whose cancer progressed after standard therapies. The main goal is to see how well this specific drug c…

This early-stage trial is testing a new treatment for multiple myeloma that has returned or stopped responding to standard therapies. Doctors will collect patients' own immune cells, use CRISPR gene-editing technology to reprogram them to attack cancer, then infuse them back into…

This early-stage study is testing whether a personalized cancer vaccine, made from a patient's own tumor and immune cells, is safe and works well when given alongside an approved drug called elranatamab. The goal is to see if this combination can better control multiple myeloma i…

This study is testing a new combination of four medications for people whose multiple myeloma has come back or stopped responding to prior treatments. The main goal is to see if this combination can shrink the cancer so effectively that it becomes undetectable by very sensitive t…

This early-stage study is testing a new combination of three drugs for patients with multiple myeloma that has come back or stopped responding to standard treatments. The main goals are to find the safest and most effective dose and to see how well the combination works. The tria…

This study is testing if different doses and timing of the drug belantamab mafodotin can work better for people with multiple myeloma that has come back or stopped responding to other treatments. The drug is designed to target and kill myeloma cells. Researchers want to see if th…

This study is testing whether using a drug called talquetamab before a personalized cell therapy (cilta-cel) is safe and feasible for people with multiple myeloma that has returned or stopped responding to treatment. The research will enroll 31 adults who have already tried at le…

This study is testing a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—to see if it can control multiple myeloma that has come back or stopped responding to other treatments and has spread to form tumors in soft tissues or organs. It will involve about 28 …

This study aims to find the best way to prevent taste changes (dysgeusia) that can occur when taking the myeloma drug talquetamab. About 130 adults with relapsed or hard-to-treat multiple myeloma will try different preventive treatments. Researchers will carefully measure taste c…

This study is testing whether a personalized exercise program in the weeks before CAR-T cell therapy can help older adults with recurrent multiple myeloma. Researchers want to see if this 'prehabilitation' improves patients' physical strength, fitness, and quality of life both be…